Numerous clinical studies have shown that T1D patients who have an “insulinogenic reserve,” also referred to as being “C-peptide positive,” experience diminished glucose variability (25–31) and enhanced plasma glucagon responses to insulin-induced hypoglycemia (26–28, 30, 32). This evidence concerns the gene GCG and Hypoglycemia.